Journals / Medical Science and Discovery / 2015 / Cilt: 2 Sayı: 6

Optimal cytoreduction is the only independent prognostic factor for survival in women with ovarian clear cell carcinoma

Pages
345–51
Publication Date
2015-09-07
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Univariate and multivariate analyses were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS).Results: The majority of the patients were at stage I disease (n=21 [24.3%]).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the clinicopathological characteristics, treatment methods, survival, and prognosis of ovarian clear-cell carcinoma (OCCC).Material and Methods: All patients with OCCC who were treated between January 1998 and October 2012 were retrospectively reviewed.
📊
Key Findings & Data:After the exclusion criteria, a total of 39 women were included in the present study.
💡
Conclusion & Impact:Univariate and multivariate analyses were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS).Results: The majority of the patients were at stage I disease (n=21 [24.3%]).
🔬Design:Review & Systematic Survey
📍Scope:2012 Verileri
⚙️Variables:ovarian clear-cell carcinoma · survival · optimal cytoreduction

Abstract

Objective: To evaluate the clinicopathological characteristics, treatment methods, survival, and prognosis of ovarian clear-cell carcinoma (OCCC).Material and Methods: All patients with OCCC who were treated between January 1998 and October 2012 were retrospectively reviewed. After the exclusion criteria, a total of 39 women were included in the present study. Univariate and multivariate analyses were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS).Results: The majority of the patients were at stage I disease (n=21 [24.3%]). All patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Additionally only pelvic, and pelvic plus para-aortic lymphadenectomy was done in 8 (20.5%) and 19 (48.8%) women, respectively. Optimal cytoreductive surgery was achieved in 26 (66.7%) patients. Recurrences occurred in 11 (28.2%) patients. The median follow-up period was 51 months (range 4 – 132 months). The 5-year PFS and OS rates were 47% and 54%, for all patients. The 5-year OS rates for women with early (stage I and II) and advanced (stage III and IV) stage disease were 56.4% and 38.1%, respectively. Multivariate analysis confirmed optimal cytoreduction as the only independent predictor of OS [Odds ratio (OR) 21.212, 95% confidence interval (CI) 5.259–85.556, (p<0.001)]Conclusion: Optimal cytoreductive surgery is the only independent good prognostic factor for survival in patients with OCCC.

🔖

Cite This Article

SOLMAZ, U., MAT, E., EKİN, A., DERELİ, L., TURAN, Ö., DEMİRTAS, G., GEZER, C., HASDEMİR, P., SAYHAN, S., SANCİ, M. (2015). Optimal cytoreduction is the only independent prognostic factor for survival in women with ovarian clear cell carcinoma. Medical Science and Discovery, Cilt: 2 Sayı: 6, 345–51. https://ajindex.com/articles/1003132

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
  2. Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DG; Vancouver Ovarian Clear Cell Symposium Speakers. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 2011;121:407-15 del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012;126:481-90. Schiller W. Mesonephroma ovarii. Am J Cancer 1939;35:1-21
  3. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW,et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60:412-7
  4. Kennedy A W, Biscotti C V, Hart W R, Webster D. Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989;32:342-9.
  5. Czernobilsky B, Silverman BB, Enterline HT. Clear-cell carcinoma of the ovary. A clinicopathologic analysis of pure and mixed forms and comparison with endometrioid carcinoma. Cancer. 1970;25:762-72.
  6. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989;32:65-71
  7. Crozier MA, Copeland LJ, Silva EG, Gershenson DM, Stringer CA. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989;35:199-203. Pectasides D1, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006;102:285-291.
  8. Timmers PJ, Zwinderman AH, Teodorovic I, Vergote I, Trimbos JB. Clear Cell Carcinoma Compared to Serous Carcinoma in Early Ovarian Cancer Same Prognosis in a Large Randomized Trial. Int J Gynecol Cancer. 2009;19: 88-93
  9. Doshi N, Tobon H. Primary clear cell carcinoma of the ovary. An analysis of 15 cases and a review of the literature. Cancer. 1977;39:2658-2664.
  10. Fine G, Clarke HD, Horn RC. Mesonephroma of the ovary. A clinical, morphological, and histogenic appraisal. Cancer. 1973;31:398-410.
  11. Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J, et al. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep. 2000;7:327-331.
  12. Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Gynecol. 1971;37:860-867. Russel P. The pathologi